Système de radiothérapie peropératoire
Nous contacter

ZEISS INTRABEAM 600

Combiner chirurgie et radiothérapie en un seul acte.

Précision locale

Le temps compte

Performances éprouvées

Précision locale

L'émetteur (XRS) avec une large gamme d'applicateurs de différentes formes, tailles et diamètres permet au praticien d'adapter le faisceau de radiation à la forme et à la taille de la tumeur et d'accroître la stérilisation du lit tumoral.1 Une diffusion limitée du rayonnement épargne les tissus environnants et organes à risques, réduisant ainsi les effets indésirables.2

Gamme d'applicateurs ZEISS INTRABEAM®: pour différentes applications

ZEISS INTRABEAM Applicateurs sphériques

Les applicateurs sphériques ZEISS INTRABEAM peuvent être utilisés pour l'irradiation peropératoire du lit tumoral après résection, par exemple lors de la chirurgie conservatrice du sein. 

ZEISS INTRABEAM Applicateur à aiguille

L'applicateur aiguille ZEISS INTRABEAM peut être utilisé pour l'irradiation interstitielle de tumeurs, par exemple dans le traitement des métastases vertébrales ou les tumeurs du cerveau. 

ZEISS INTRABEAM Applicateurs de surface

Les applicateurs plats ZEISS INTRABEAM peuvent être utilisés dans le traitement du lit tumoral de zone exposées chirurgicalement, par exemple sur les tumeurs de l'appareil digestif. 

ZEISS INTRABEAM Applicateurs de surface

Les applicateurs de surface ZEISS INTRABEAM peuvent être utilisés dans le traitement du lit tumoral à la surface du corps, par exemple l'irradiation des cancers de la peau non-mélanomes. 

Le temps compte

La RTPO immédiate limite l'activité cellulaire de cicatrisation du lit tumoral et donc la récidive. Elle peut également permettre de raccourcir la durée du traitement complet et réduire le volume de soins sans compromettre les résultats. Le patient peut bénéficier d'un traitement complet durant son anesthésie.3,4

Flux de traitement - Etude TARGIT-A

Durée de traitement raccourci

La durée moyenne des traitements post-opératoires de 6.5 semaines peut être réduite entre 3 et 5 semaines, voire supprimée pour les patients éligibles à une RTPO lors d'une chirurgie conservatrice du sein.2  

Performances éprouvées

ZEISS INTRABEAM + de 250 publications évaluées par des pairs et + de 20 ans d'études dans plus de 30 pays confirmant la valeur clinique des options de traitement RTPO personnalisées et centrées sur le patient. 

Les études sur INTRABEAM dans le monde

Visualiser les récentes études sur la carte

Morgantown, Etats-Unis | Tumeurs du cerveau

Cifarelli, C., et al.

West Virginia University Hospital

Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study

Evidence: Level 2
No. of patients: 54
Median follow-up: 7.2 months
No. of centers: 3

Reference: Cifarelli, C.P., et al. (2019). Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study. J Neurooncol 145, 391 397. https://doi:10.1007/s11060-019-03309-6

Also in Morgantown - Vargo, J.A., et al. (2018) investigating the feasibility of dose escalation for IORT vs. SRS during brain metastases resection.

Cleveland, Etats-Unis | Métastase du cerveau

Weil, R.J., et al.

Cleveland Clinic

Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes

Clinical outcomes for IORT with INTRABEAM® to the cavity during brain metastasis resection show comparable results for local and distant control and long-term survival compared to conventional teatment modalities.

Evidence: Level 2
No. of patients: 23
Median follow-up: 22.0 months
No. of centers: 1

Reference: Weil, R. J., et al. (2015). Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes, Journal of Neurosurgery JNS, 122(4), 825-832

Nantes, France | Cancer du sein

Le Blanc, M., et al.

Institut De Cancérologie De L'Ouest - Nantes

Medico Economic Study, Randomized, Comparing Intraoperative Radiotherapy With Intrabeam® on Surgical Resection Bed Versus Conventional Surgery + EBRT in Postmenopausal Patients Operated by Conservative Surgery for Low Risk Breast Cancer

Scope: Comparison of IORT with INTRABEAM® versus EBRT, in terms of costs, local-regional survival without recurrence, rate of early and late complications, impact aesthetic outcome and quality of life of patients.

Evidence: Level 1
No. of patients: 246
No. of centers: 9

Reference: Clinical Trial Identifier: NCT03637738

Guangdong, Chine | Cancer du sein

Ning, L., et al.

Guangdong Academy of Medical Sciences

Intra-operative Radiotherapy After Breast-conserving Surgery in Treating Women With Ductal Carcinoma in Situ Breast Cancer

Scope: Effectiveness measurement of intraoperatve radiotherapy (IORT) during breast-conserving surgery for low grade ductal carcinoma in situ breast cancer.

Evidence: Level 1
No. of patients: 222
No. of centers: 1

Reference: Clinical Trial Identifier: NCT02389673

Londres, Angleterre | Cancer du sein

Vaidya, J., et al.

University College London

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial

Clinical outcomes of single-dose IORT delivered during breast-conserving surgery show significantly fewer non-breast-cancer deaths compared to EBRT.

Evidence: Level 1
No. of patients: 3451
Median follow-up: 29.0 months
No. of centers: 33

Reference: Vaidya, J. S., et al. (2014). Risk-adapted targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. The Lancet, 383(9917), 603–613.

Also active in London - Vaidya, J., et al., with TARGIT-B comparing IORT Boost with EBRT Boost in early-stage breast cancer, 1790 patients in 35 centers planned (Clinical Trial Identifier: NCT01792726)

Mannheim, Allemagne | Glioblastome multiforme (Cerveau)

Giordano, F., et al.

University Medical Center Mannheim

A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)

Evidence: Level 1
No. of patients: 314 planned
No. of centers: 20 planned

Reference: Clinical Trial Identifier: NCT02685605

Other Level 1 & 2 studies in Mannheim - INTRAGO I (Brain), a pooled analysis (Brain), TARGIT-E (Breast) and Kypho-IORT (Spine)

Seoul, Corée du sud | Cancer du pancréas

Lee, I.J., et al.

Gangnam Severance Hospital

A Prospective, Phase II Study Investigating Efficacy of Intraoperative Radiation Therapy for Resectable Pancreatic Cancer

Scope: Investigation of IORT efficacy resectable pancreatic adenocarcinoma patients with regards to local recurrence rate after surgical resection with and without IORT.

Evidence: Level 2
No. of patients: 42 planned
No. of centers: 1

Reference: Clinical Trial Identifier: NCT03273374

Changchun, Chine | Cancer du rectum

Wang, M., et al.

Second Hospital of Jilin University

Single Center Study of Intraoperative Radiotherapy for Middle and Low Rectal Cancer in the Standard of Peritoneal Inversion Rectal Cancer

Scope: Assessment of post-op acute complication and short-term acute efficacy for patients with middle and low rectal cancer treated with IORT after intersphincteric resection.

Evidence: Level 1
No. of patients: 50
No. of centers: 1

Reference: Clinical Trial Identifier: NCT03209336

Chicago, Etats-Unis | Tumeurs du cerveau récurrentes

Kalapurakal, J.A., et al.

Northwestern Memorial Hospital

Final Results of a Phase I Dose Escalation Study of Intraoperative Radiation Therapy in Children with Radiation Recurrent Posterior Fossa Tumors

Clinical outcomes of IORT after maximal tumor resection showed no irreversible grade 3 or higher toxicity in patients.

Evidence: Level 2
No. of patients: 11
Median follow-up: 33.0 months
No. of centers: 1

Reference: Kalapurakal, J.A., et al. (2010). Final Results of a Phase I Dose Escalation Study of Intraoperative Radiation Therapy in Children with Radiation Recurrent Posterior Fossa Tumors. Radiation Oncology, 78(3) Supplement, 19-20

New York, Etats-Unis | Métastases vertébrales

Ghaly, M., et al.

Northwell Health

Kypho-Intra Operative Radiation Therapy (IORT) for Localized Spine Metastasis, Phase I/II Study

Scope: Evaluation of response rate of pain control of Kypho-IORT, feasibility, tolerability (side effects) within 90 days post-procedure, determination of clinical factors for vertebral compression fracture.

Evidence: Level 2
No. of patients: 22 planned
No. of centers: 1

Reference: Clinical Trial Identifier: NCT02987153

Learn for yourself about studies and treatment activities undertaken worldwide by your peers.

Changchun, Chine

Wang, M., et al.

Second Hospital of Jilin University

Single Center Study of Intraoperative Radiotherapy for Middle and Low Rectal Cancer in the Standard of Peritoneal Inversion Rectal Cancer

Scope: Assessment of post-op acute complication and short-term acute efficacy for patients with middle and low rectal cancer treated with IORT after intersphincteric resection.

Evidence: Level 1
No. of patients: 50
No. of centers: 1

Reference: Clinical Trial Identifier: NCT03209336

Chicago, Etats-Unis

Kalapurakal, J.A., et al.

Northwestern Memorial Hospital

Final Results of a Phase I Dose Escalation Study of Intraoperative Radiation Therapy in Children with Radiation Recurrent Posterior Fossa Tumors

Clinical outcomes of IORT after maximal tumor resection showed no irreversible grade 3 or higher toxicity in patients.

Evidence: Level 2
No. of patients: 11
Median follow-up: 33.0 months
No. of centers: 1

Reference: Kalapurakal, J.A., et al. (2010). Final Results of a Phase I Dose Escalation Study of Intraoperative Radiation Therapy in Children with Radiation Recurrent Posterior Fossa Tumors. Radiation Oncology, 78(3) Supplement, 19-20

Cleveland, Etats-Unis

Weil, R.J., et al.

Cleveland Clinic

Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes

Clinical outcomes for IORT with INTRABEAM® to the cavity during brain metastasis resection show comparable results for local and distant control and long-term survival compared to conventional teatment modalities.

Evidence: Level 2
No. of patients: 23
Median follow-up: 22.0 months
No. of centers: 1

Reference: Weil, R. J., et al. (2015). Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes, Journal of Neurosurgery JNS, 122(4), 825-832

Guanzhou, Chine

Ning, L., et al.

Guangdong Academy of Medical Sciences

Intra-operative Radiotherapy After Breast-conserving Surgery in Treating Women With Ductal Carcinoma in Situ Breast Cancer

Scope: Effectiveness measurement of intraoperatve radiotherapy (IORT) during breast-conserving surgery for low grade ductal carcinoma in situ breast cancer.

Evidence: Level 1
No. of patients: 222
No. of centers: 1

Reference: Clinical Trial Identifier: NCT02389673

Londres, Angleterre

Vaidya, J., et al.

University College London

Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial

Clinical outcomes of single-dose IORT delivered during breast-conserving surgery show significantly fewer non-breast-cancer deaths compared to EBRT.

Evidence: Level 1
No. of patients: 3451
Median follow-up: 29.0 months
No. of centers: 33

Reference: Vaidya, J. S., et al. (2014). Risk-adapted targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. The Lancet, 383(9917), 603–613.

Also active in London - Vaidya, J., et al., with TARGIT-B comparing IORT Boost with EBRT Boost in early-stage breast cancer, 1790 patients in 35 centers planned (Clinical Trial Identifier: NCT01792726)

Mannheim, Allemagne

Giordano, F., et al.

University Medical Center Mannheim

A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)

Evidence: Level 1
No. of patients: 314 planned
No. of centers: 20 planned

Reference: Clinical Trial Identifier: NCT02685605

Other Level 1 & 2 studies in Mannheim - INTRAGO I (Brain), a pooled analysis (Brain), TARGIT-E (Breast) and Kypho-IORT (Spine)

Morgantown, USA

Cifarelli, C., et al.

West Virginia University Hospital

Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study

Evidence: Level 2
No. of patients: 54
Median follow-up: 7.2 months
No. of centers: 3

Reference: Cifarelli, C.P., et al. (2019). Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study. J Neurooncol 145, 391 397. https://doi:10.1007/s11060-019-03309-6

Also in Morgantown - Vargo, J.A., et al. (2018) investigating the feasibility of dose escalation for IORT vs. SRS during brain metastases resection.

Nantes, France

Le Blanc, M., et al.

Institut De Cancérologie De L'Ouest - Nantes

Medico Economic Study, Randomized, Comparing Intraoperative Radiotherapy With Intrabeam® on Surgical Resection Bed Versus Conventional Surgery + EBRT in Postmenopausal Patients Operated by Conservative Surgery for Low Risk Breast Cancer

Scope: Comparison of IORT with INTRABEAM® versus EBRT, in terms of costs, local-regional survival without recurrence, rate of early and late complications, impact aesthetic outcome and quality of life of patients.

Evidence: Level 1
No. of patients: 246
No. of centers: 9

Reference: Clinical Trial Identifier: NCT03637738

New York, Etas-Unis

Ghaly, M., et al.

Northwell Health

Kypho-Intra Operative Radiation Therapy (IORT) for Localized Spine Metastasis, Phase I/II Study

Scope: Evaluation of response rate of pain control of Kypho-IORT, feasibility, tolerability (side effects) within 90 days post-procedure, determination of clinical factors for vertebral compression fracture.

Evidence: Level 2
No. of patients: 22 planned
No. of centers: 1

Reference: Clinical Trial Identifier: NCT02987153

Seoul, Corée du Sud

Lee, I.J., et al.

Gangnam Severance Hospital

A Prospective, Phase II Study Investigating Efficacy of Intraoperative Radiation Therapy for Resectable Pancreatic Cancer

Scope: Investigation of IORT efficacy resectable pancreatic adenocarcinoma patients with regards to local recurrence rate after surgical resection with and without IORT.

Evidence: Level 2
No. of patients: 42 planned
No. of centers: 1

Reference: Clinical Trial Identifier: NCT03273374

Les autres applications de ZEISS INTRABEAM

ZEISS INTRABEAM 600 : irradiation ciblée pour différents types de tumeurs

Brain tumors

Tumeurs du cerveau

Spinal metastases

Métastases vertébrales

Breast cancer

Cancer du sein

Gastrointestinal tumors

Tumeurs gastro-intestinales

Head & neck tumors

Tumeurs cérébrales et vertébrales

Skin cancer

Cancer de la peau

Nous contacter

Vous avez besoin de conseils ou de plus d’informations sur l’un de nos produits ?

Rester informés

Inscrivez-vous à notre newsletter pour découvrir toutes nos actualités

  • 1 Vargo, J. A., et al. (2018). Feasibility of dose escalation using intraoperative radiotherapy following resection of large brain metastases compared to post-operative stereotactic radiosurgery. Journal of Neuro-Oncology, 140(2), 413–420.
  • 2 Vaidya, J. S. et al. (2020). Long-term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ, 370, m2836. https://doi.org/10.1136/bmj.m2836
  • 3 Belletti, B., et al. (2008). Targeted Intraoperative Radiotherapy Impairs the Stimulation of Breast Cancer Cell Proliferation and Invasion Caused by Surgical Wounding. Clinical Cancer Research, 14(5), 1325–1332.
  • 4 Fabris, L., et al. (2016). Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. Oncogene, (November 2015), 1–13.

INTRABEAM® 600 (classe IIb) est un système utilisé dans les traitements de radiothérapie peropératoire, de surface et intracavitaire. Fabriqué par : Carl Zeiss Meditec AG. Distribué par : Carl Zeiss Meditec France. Organisme notifié : DQS Medizinprodukte GmbH. Nous vous invitons avant toute utilisation à lire attentivement et dans leur totalité les instructions figurant dans les guides utilisateurs remis aux professionnels de santé. Pris en charge par les organismes d’assurance maladie dans certaines situations : consultez ameli.fr.